Drug maker GSK invests in gene profiling services

Drug maker GSK invests in gene profiling services

Drug maker GlaxoSmithKline says second-quarter revenue was 7.3 billion pounds , up 4 percent when discounting currency shifts, amid a promising performance of a new shingles treatment. Sales of the shingles treatment Shingrix made 167 million pounds, and the company increased its forecast for 2018 sales of the drug to as much as 650 million pounds.

from Biotech News